Biotechnology

Techseriesinsight > Blog > News > Biotechnology

July 22, 2025
PRNewswire
Biotechnology, Networking, News

Nanoscope Shares Opsin Tech Insights

Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene therapies for patients suffering vision loss from retinal degenerative diseases, today announced the publication of a...

July 21, 2025
PRNewswire
Biotechnology, News

Compugen Doses First Ovarian Cancer Patient

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that the first patient was dosed in the...

July 21, 2025
Business Wire
Biotechnology, Healthcare, News

TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a...

July 21, 2025
PRNewswire
Biotechnology, News

Synthego Announces Successful Close of Acquisition by Perceptive Advisors

Synthego, a leading provider of CRISPR solutions, today announced the successful closing of the acquisition of substantially all of its assets by funds managed by Perceptive Advisors, a leading...

July 18, 2025
PRNewswire
Biotechnology, News

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects...

July 18, 2025
Business Wire
Biotechnology, News

BMS Reveals Reblozyl Phase 3 Results

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood...

July 17, 2025
Business Wire
Biotechnology, News

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S....

July 17, 2025
Business Wire
Biotechnology, News

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study

PureTech Health plc A clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, (“Seaport”) a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and...

July 17, 2025
PRNewswire
Biotechnology, Healthcare, News

SK bioscience Advances Adjuvanted Flu Vaccine to Phase 1/2 Trial

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has submitted an Investigational New Drug...

July 17, 2025
PRNewswire
Biotechnology, News

Saluda Medical Announces U.S. Launch of EVA Sensing Technology for the Evoke SmartLoop Neuromodulation System

Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced the...